- Home
- KIO vs CTNM Comparison
KIO vs CTNM Comparison
Compare KIO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KIO | CTNM |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | 2400 | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.7M | 416.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | KIO | CTNM |
|---|---|---|
| Price | $11.71 | $14.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 136.5K | ★ 280.5K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $3.35 |
| 52 Week High | $13.59 | $15.48 |
Technical Indicators
Market Signals| Indicator | KIO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 68.28 |
| Support Level | $11.50 | $13.58 |
| Resistance Level | $11.74 | $15.48 |
| Average True Range (ATR) | 0.08 | 1.06 |
| MACD | 0.02 | 0.29 |
| Stochastic Oscillator | 90.35 | 85.34 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.